News &amp; Updates

For patients undergoing peritoneal dialysis, parathyroidectomy yields bigger increases in the bone mineral density (BMD) of lumbar spine and femoral neck as well as decreases in osteopenia/osteoporosis, according to a study.

Surgery bests oral med for boosting bone density in dialysis patients

Breaking ground in migraine management: First Consensus Guidelines from the Headache Society of Singapore

In a pioneering effort, the Headache Society of Singapore (HSS) has released the first edition of consensus guidelines focusing on the approach to headache disorders and management of migraine. Amid a rapidly growing array of therapeutic options, standardizing treatment approaches is crucial. These guidelines provide a pivotal resource for healthcare professionals navigating the complex landscape of headache disorders, with a special focus on migraine management in adults.

Breaking ground in migraine management: First Consensus Guidelines from the Headache Society of Singapore

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

For older adults with chronic kidney disease (CKD) who are initiating a disease-modifying antirheumatic drug (DMARD), low-dose methotrexate appears to be associated with a heightened 90-day risk of serious adverse events compared with hydroxychloroquine, as shown in a study.

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?

Combination therapy does not appear to have beneficial effects in terms of progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), and incidence of adverse events compared with monotherapy in patients with advanced nonsmall cell lung cancer (NSCLC) who failed first-line treatment with an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, a study has shown.

How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?

05 Dec 2023

NOACs help improve outcomes in AF with vascular disease

A history of vascular disease appears to contribute to worse long-term outcomes in patients with atrial fibrillation (AF), but treatment with oral anticoagulation (OAC) helps, suggests a recent study.

NOACs help improve outcomes in AF with vascular disease

Novel therapies tied to drop in colectomy rate in paediatric UC

The risk of colectomy in paediatric onset ulcerative colitis (UC) has significantly decreased at the population level along with an increase in the use of immunosuppressants and antitumour necrosis factor (anti-TNF), reports a study.

Novel therapies tied to drop in colectomy rate in paediatric UC

Remibrutinib improves CSU symptoms in phase III trials

Treatment with the investigational, oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib improves symptoms in patients with chronic spontaneous urticaria (CSU) inadequately controlled on antihistamines, the phase III REMIX-1 and -2 studies have shown.

Remibrutinib improves CSU symptoms in phase III trials

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

In the phase III REMAIN-2 trial, add-on recaticimab – a novel, long-acting anti-PCSK9 monoclonal antibody (mAb) – led to reductions in bad cholesterol and other lipids in patients with non-familial hypercholesterolaemia (non-FH) and mixed hyperlipidaemia inadequately controlled on background statin therapy.

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

Fezolinetant superior to other non-HTs at reducing bothersome VMS due to menopause

Treatment with fezolinetant 45 mg outperforms other nonhormone therapies (non-HTs) in terms of minimizing the frequency of moderate-to-severe vasomotor symptoms (VMS) in women undergoing menopause, according to a study from the US.

Fezolinetant superior to other non-HTs at reducing bothersome VMS due to menopause

Intermittent dosing of dual HIV therapy for HIV disappoints in DUETTO trial

Four-day-a-week dosing of dual therapy for HIV performs similarly to daily doses in terms of sustaining viral suppression in the DUETTO trial. However, virological failure (VF) and drug resistance rates were higher with the 4-day/week dosing regimen.

Intermittent dosing of dual HIV therapy for HIV disappoints in DUETTO trial